119 related articles for article (PubMed ID: 38520417)
1. Receptor Tyrosine Kinase EPHA2 Drives Epidermal Differentiation through Regulation of EGFR Signaling.
Perez White BE; Cable CJ; Shi B; Ventrella R; Kaplan N; Kobeissi A; Higuchi Y; Balu A; Murphy ZR; Kumar P; Getsios S
J Invest Dermatol; 2024 Feb; ():. PubMed ID: 38520417
[TBL] [Abstract][Full Text] [Related]
2. EphA2 proteomics in human keratinocytes reveals a novel association with afadin and epidermal tight junctions.
Perez White BE; Ventrella R; Kaplan N; Cable CJ; Thomas PM; Getsios S
J Cell Sci; 2017 Jan; 130(1):111-118. PubMed ID: 27815408
[TBL] [Abstract][Full Text] [Related]
3. Ligand targeting of EphA2 enhances keratinocyte adhesion and differentiation via desmoglein 1.
Lin S; Gordon K; Kaplan N; Getsios S
Mol Biol Cell; 2010 Nov; 21(22):3902-14. PubMed ID: 20861311
[TBL] [Abstract][Full Text] [Related]
4. Alteration of the EphA2/Ephrin-A signaling axis in psoriatic epidermis.
Gordon K; Kochkodan JJ; Blatt H; Lin SY; Kaplan N; Johnston A; Swindell WR; Hoover P; Schlosser BJ; Elder JT; Gudjonsson JE; Getsios S
J Invest Dermatol; 2013 Mar; 133(3):712-722. PubMed ID: 23190894
[TBL] [Abstract][Full Text] [Related]
5. Quantitative chemical proteomics reveals new potential drug targets in head and neck cancer.
Wu Z; Doondeea JB; Gholami AM; Janning MC; Lemeer S; Kramer K; Eccles SA; Gollin SM; Grenman R; Walch A; Feller SM; Kuster B
Mol Cell Proteomics; 2011 Dec; 10(12):M111.011635. PubMed ID: 21955398
[TBL] [Abstract][Full Text] [Related]
6. Cell adhesion and EGFR activation regulate EphA2 expression in cancer.
Larsen AB; Stockhausen MT; Poulsen HS
Cell Signal; 2010 Apr; 22(4):636-44. PubMed ID: 19948216
[TBL] [Abstract][Full Text] [Related]
7. EphA2 Transmembrane Domain Is Uniquely Required for Keratinocyte Migration by Regulating Ephrin-A1 Levels.
Ventrella R; Kaplan N; Hoover P; Perez White BE; Lavker RM; Getsios S
J Invest Dermatol; 2018 Oct; 138(10):2133-2143. PubMed ID: 29705292
[TBL] [Abstract][Full Text] [Related]
8. Skin Barrier Defects Caused by Keratinocyte-Specific Deletion of ADAM17 or EGFR Are Based on Highly Similar Proteome and Degradome Alterations.
Tholen S; Wolf C; Mayer B; Knopf JD; Löffek S; Qian Y; Kizhakkedathu JN; Biniossek ML; Franzke CW; Schilling O
J Proteome Res; 2016 May; 15(5):1402-17. PubMed ID: 27089454
[TBL] [Abstract][Full Text] [Related]
9. Activation of the epidermal growth factor receptor signal transduction pathway stimulates tyrosine phosphorylation of protein kinase C delta.
Denning MF; Dlugosz AA; Threadgill DW; Magnuson T; Yuspa SH
J Biol Chem; 1996 Mar; 271(10):5325-31. PubMed ID: 8621384
[TBL] [Abstract][Full Text] [Related]
10. Chemical Proteomics Uncovers EPHA2 as a Mechanism of Acquired Resistance to Small Molecule EGFR Kinase Inhibition.
Koch H; Busto ME; Kramer K; Médard G; Kuster B
J Proteome Res; 2015 Jun; 14(6):2617-25. PubMed ID: 25963923
[TBL] [Abstract][Full Text] [Related]
11. Spleen Tyrosine Kinase Mediates EGFR Signaling to Regulate Keratinocyte Terminal Differentiation.
Wu NL; Huang DY; Wang LF; Kannagi R; Fan YC; Lin WW
J Invest Dermatol; 2016 Jan; 136(1):192-201. PubMed ID: 26763439
[TBL] [Abstract][Full Text] [Related]
12. Activation of the EGFR gene target EphA2 inhibits epidermal growth factor-induced cancer cell motility.
Larsen AB; Pedersen MW; Stockhausen MT; Grandal MV; van Deurs B; Poulsen HS
Mol Cancer Res; 2007 Mar; 5(3):283-93. PubMed ID: 17374733
[TBL] [Abstract][Full Text] [Related]
13. EGFR regulation of epidermal barrier function.
Tran QT; Kennedy LH; Leon Carrion S; Bodreddigari S; Goodwin SB; Sutter CH; Sutter TR
Physiol Genomics; 2012 Apr; 44(8):455-69. PubMed ID: 22395315
[TBL] [Abstract][Full Text] [Related]
14. Expression of the receptor tyrosine kinase EphA2 is increased in smokers and predicts poor survival in non-small cell lung cancer.
Brannan JM; Dong W; Prudkin L; Behrens C; Lotan R; Bekele BN; Wistuba I; Johnson FM
Clin Cancer Res; 2009 Jul; 15(13):4423-30. PubMed ID: 19531623
[TBL] [Abstract][Full Text] [Related]
15. EphA2/Ephrin-A1 Mediate Corneal Epithelial Cell Compartmentalization via ADAM10 Regulation of EGFR Signaling.
Kaplan N; Ventrella R; Peng H; Pal-Ghosh S; Arvanitis C; Rappoport JZ; Mitchell BJ; Stepp MA; Lavker RM; Getsios S
Invest Ophthalmol Vis Sci; 2018 Jan; 59(1):393-406. PubMed ID: 29351356
[TBL] [Abstract][Full Text] [Related]
16. Crosstalk of the EphA2 receptor with a serine/threonine phosphatase suppresses the Akt-mTORC1 pathway in cancer cells.
Yang NY; Fernandez C; Richter M; Xiao Z; Valencia F; Tice DA; Pasquale EB
Cell Signal; 2011 Jan; 23(1):201-12. PubMed ID: 20837138
[TBL] [Abstract][Full Text] [Related]
17. EGFR inhibitors switch keratinocytes from a proliferative to a differentiative phenotype affecting epidermal development and barrier function.
Joly-Tonetti N; Ondet T; Monshouwer M; Stamatas GN
BMC Cancer; 2021 Jan; 21(1):5. PubMed ID: 33402117
[TBL] [Abstract][Full Text] [Related]
18. Epidermal ADAM17 maintains the skin barrier by regulating EGFR ligand-dependent terminal keratinocyte differentiation.
Franzke CW; Cobzaru C; Triantafyllopoulou A; Löffek S; Horiuchi K; Threadgill DW; Kurz T; van Rooijen N; Bruckner-Tuderman L; Blobel CP
J Exp Med; 2012 Jun; 209(6):1105-19. PubMed ID: 22565824
[TBL] [Abstract][Full Text] [Related]
19. Disruption of EphA2 receptor tyrosine kinase leads to increased susceptibility to carcinogenesis in mouse skin.
Guo H; Miao H; Gerber L; Singh J; Denning MF; Gilliam AC; Wang B
Cancer Res; 2006 Jul; 66(14):7050-8. PubMed ID: 16849550
[TBL] [Abstract][Full Text] [Related]
20. A novel DLX3-PKC integrated signaling network drives keratinocyte differentiation.
Palazzo E; Kellett MD; Cataisson C; Bible PW; Bhattacharya S; Sun HW; Gormley AC; Yuspa SH; Morasso MI
Cell Death Differ; 2017 Apr; 24(4):717-730. PubMed ID: 28186503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
